Проблемы диагностики и лечения первично операбельного рака молочной железы


https://doi.org/10.17709/2409-2231-2015-2-2-35-43

Полный текст:


Аннотация

Рак молочный железы - гетерогенное заболевание, обладающее генотипической и фенотипической вариабельностью. Фенотипическое разнообразие опухолей напрямую связано с генотипическими вариациями, которые можно определить с помощью анализа экспрессии генов при комплексном иммуногистохимическом исследовании. На сегодняшний день существует великое множество методик хирургического лечения – от малоинвазивных до радикальных-, вариабельных по количеству этапов, наличия и объема реконструктивных приемов. На передний план выходят органосохраняющие операции.


Об авторах

Е. А. Трошенков
МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России 125284, Российская Федерация, г. Москва, 2-ой Боткинский проезд, дом 3
Россия
к.м.н., ведущий хирург отделения общей онкологии МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России


А. А. Костин
ФГБУ «НМИРЦ» Минздрава России 249036, Российская Федерация, Калужская область, г. Обнинск, ул. Королёва, д. 4
Россия

д.м.н., профессор, первый заместитель генерального директор ФГБУ «НМИРЦ» Минздрава России, заведующий кафедрой урологии, онкологии и радиологии ФПК МР РУДН



Список литературы

1. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D. Panel members† Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of Oncology. 2013; 24.(9): 2206-2223.

2. Park S., Koo J., Park H.S., et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;.21: 488–492.

3. Park S., Park H.S., Kim S.I. The impact of a focally positive resection margin on the local control in patients treated with breast-conserving therapy. J Clin Oncol.2011; 5:.600-608.

4. Gobardhan P.D., de Wall L.L., van der Laan L., ten Tije A.J. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. Ann Oncol. 2013; 24(3): 668-673.

5. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2010; 5: 5–23.

6. Cancello G. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Annals of Oncology. 2013; 24: 661–668

7. Oh D.S., Troester M.A., Usary J., et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006; 24: 1656–1664.

8. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005; 11: 5678–5685.

9. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100: 8418–8423.

10. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009; 69: 4116–4124.

11. Prat A., Parker J.S., Karginova O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12: R68.

12. Marcom P.K., Isaacs C., Harris L., et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007; 102: 43–49.

13. Cui X., Schiff R., Arpino G., et al.. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;.23: 7721–7735.

14. Rakha E.A., El-Sayed M.E., Green A.R., et al.. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007; 25: 4772–4778.

15. Creighton C.J., Kent Osborne C., van de Vijver M.J., et al.. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009; 114: 287–299.

16. Cuzick J., Dowsett M., Pineda S., et al.. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011; 29: 4273–4278.

17. Hugh J., Hanson J., Cheang M.C., et al.. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an Immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol. 2009; 27: 1168–1176.

18. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 Index, HER2 Status, and prognosis of patients with luminal B breast Cancer. J Natl Cancer Inst. 2009; 101: 736–750.

19. Gayathri Nagaraj, Ma C.X. Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor–Positive, HER2-Negative Breast Cancer: Challenges and Considerations . JNCCN. 2013; 11(3): 246-251.

20. Волченко А.А., Чиссов В.И., Зикиряходжаев А.Д. Выбор реконструктивно-пластических операций при комплексном лечении больных раком молочной железы. Онкология. Журнал им. П.А. Герцена. 2014; № 1: 3-9.

21. Bleyer A., Welch H.W. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. N Engl J Med. 2012; 367: 1998- 2005.

22. Besluit van 16 juli 2001, houdende vaststelling van het besluit stralingsbescherming.12. 2. URL: http://www.sbng.nl (accessed 20.04.2015).

23. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.

24. Cianfrocca M., Goldstein L.J. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004; 9: 606–616.

25. Dowsett M., Lopez-Knowles E., Sidhu K., et al. Comparison of PAM50 risk of recurrence (ROR) score with Oncotype DX and IHC4 for predicting residual risk of RFS and distant-(D)RFS after endocrine therapy: a transATAC study. Cancer Res. 2011; 71(3): 4–5.

26. Dabbs D.J., Klein M.E., Mohsin S.K., et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol. 2011; 29: 4279–4285.

27. Baehner F.L., Achacoso N., Maddala T., et al. Human epidermal growth factor receptor 2 assessment in a case–control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010; 28: 4300–4306.

28. Hammond M.E., Hayes D.F., Dowsett M. et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16): 2784–2795.

29. Hammond M.E., Hayes D.F., Wolff A.C. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011; 29: e458.

30. Vaz-Luis I., Winer E.P., Lin N. U. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Annals of Oncology. 2013;.24: 283–291.

31. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24: 3726–3734.

32. Carlson R.W., Allred D.C., Anderson B.O., et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3, 2012. URL: www.nccn.org (accessed 17.01.2013).

33. Mook S., Schmidt M.K., Rutgers E.J., et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009; 10: 1070–1076.

34. Caruso F., Ferrara M., Castiglione G., Trombetta G., De Meo L., Catanuto G., Carillio G. Nipple sparing subcutaneous mastectomy: sixty-six months follow-up. Eur J Surg Oncol.2006; 32(9): Р.937.

35. Sacchini V.S., de Alcantara Filho P., Capko D., Barry J.M., Morrow M. Nipple-sparing mastectomy for breast cancer and risk-reducing surgery: the Memorial Sloan-Kettering Cancer Center experience. Ann Surg Oncol. 2011; 18(11): 3117-22.

36. Komorowski A.L., Zanini V., Regolo L., Carolei A., Wysocki W.M., Costa A. Necrotic complications after nipple- and areola-sparing mastectomy.World J Surg. 2006; 30(8): 1410.

37. Galimberti V., Cole B.F., Zurrida S.. et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncol. 2013; 14: 297–305.

38. Giuliano A.E., Hunt K.K., Ballman K.V.. et al. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305: 569–575.

39. Voogd A.C., van Oost F.J., Rutgers E.J., et al. Long term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J cancer. 2005; 41: 2637-2644.

40. Hughes J.H., Mason M.C., Gray R.J., et al. A Multi-site validation trial of radioactive seed localization as an alternative to wire localization. Breast J. 2008; 14: 153-157.

41. Lovrics P.J., Goldsmith C.H., Hodgson N., et al. A multicentered, randomized, controlled trial comparing radio guided seed localization to standard wire localization for nonpalpable invasive and in situ breast carcinomas. Ann Surg Oncol. 2011; 18: 3407-3414.

42. Centraal BegeleidingsOrgaan (CBO). Fysieke en cognitieve effecten, voorlichting en psychosociale zorg. In: Richtlijn mammacarcinoom 2008. P. 222-224.

43. Krekel N.M., Zonderhuis B.M., Scheurs H.W.H., et al. Ultrasound-guided breast-sparing surgery to improve cosmetic outcomes and quality of life. A prospective multicentre randomized controlled clinical trial comparing ultrasound-guided surgery to traditional palpation guided surgery (COBALT trial). BMC Surg. 2011; 16: 11-18.

44. Pleijhuis R.G., Langhout G.C., Helfrich W., et al. Near-infrared fluorescence (NIRF) imaging in breast-conserving surgery: assessing intraoperative techniques in tissue-simulating breast phantoms. Eur J Surg oncol.. 2011;.37: 32-39.

45. Espinosa-Bravo M., Sao Aviles A., Esqueva A., et al. Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods. Eur J Surg Oncol. 2011; 37: 1038-1043.

46. Krekel N.M., Zonderhuis B.M., Stockmann H.B., et al. A comparison of three methods for nonpalpable breast cancer excision. Eur J Surg Oncol. 2011; 37: 109-115.

47. Weissenbacher T.M., Zschage M., Janni W., et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat. 2010; 122: 27-34.

48. Bauman L., Barth R.J., Rosenkranz K.M.. Breast conservation in women with multifocal-multicentric breast cancer: is it feasible? Ann Surg Oncol. 2010; 17: 325-329.

49. Yerushalmi R., Tyldesley S., Woods R., et al. Is breast conserving therapy a safe option for patients with tumor multicentricity and multifocality. Ann Oncol. 2012; 23: 876-881.

50. Massarweh S., Osborne C.K., Jiang S., et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006; 66: 8266–8273.

51. Guarneri V., Frassoldati A., Bottini A., et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) [abstract]. J Clin Oncol. 2011; 29: a507.

52. Baselga J., Bradbury I., Eidtmann H., et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet.2012; 379: 633–640.

53. Shou J., Massarweh S., Osborne C.K., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96: 926–935.

54. Viale G., Regan M.M., Maiorano E., et al.. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007; 25: 3846–3852.

55. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365: 1273–1283.

56. Perez E.A., Romond E.H., Suman V.J., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2- positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B- 31. J Clin Oncol. 2011; 29: 3366–3373.

57. Albain K., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive,oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncology. 2010; 11(1): 55–65.

58. Hornberger J., Chien R. Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice. In Poster Presented at the St Gallen International Breast Cancer Conference, St Gallen, Switzerland, March. 2011; Abstract: 201.


Дополнительные файлы

Для цитирования: Трошенков Е.А., Костин А.А. Проблемы диагностики и лечения первично операбельного рака молочной железы. Исследования и практика в медицине. 2015;2(2):35-43. https://doi.org/10.17709/2409-2231-2015-2-2-35-43

For citation: Troshenkov E.A., Kostin A.A. Problems of diagnosis and treatment of primary operable breast cancer. Research'n Practical Medicine Journal. 2015;2(2):35-43. (In Russ.) https://doi.org/10.17709/2409-2231-2015-2-2-35-43

Просмотров: 593

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN: 2409-2231 (Print)
ISSN: 2410-1893 (Online)